Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based...

Area of Science:

• Oncology
• Dermatology
• Surgical Pathology

Background:

• Sentinel node metastasis is a critical prognostic factor in melanoma.
• Recent clinical trials challenge the necessity of lymph node dissection (LND) in specific patient groups.
• Evolving evidence necessitates a re-evaluation of melanoma treatment protocols.

Purpose of the Study:

• To update clinicians on evidence regarding sentinel node-positive melanoma management.
• To identify key factors influencing treatment decisions for these patients.
• To propose a decision-making algorithm for managing sentinel node-positive melanoma.

Main Methods:

• Review of current clinical trial data and evidence.
• Analysis of factors including metastatic spread, predictors, and adjuvant therapies.
• Development of a clinical decision-making algorithm.

Main Results:

• Lymph node dissection (LND) is not associated with survival benefit in patients with sentinel node metastasis.
• Low-risk sentinel node metastasis (tumor load ≤1mm) does not warrant LND.
• Several factors, including routes of spread and adjuvant therapy, are crucial for treatment planning.

Conclusions:

• The current evidence does not support routine lymph node dissection for all patients with sentinel node-positive melanoma.
• A nuanced approach considering tumor characteristics and patient factors is essential.
• A proposed algorithm aims to guide clinical decision-making in this setting.